Use

Exon 10 MPL mutations, most commonly W515 and S505, are present in approximately 5‑10% of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET). MPL and CALR mutations have been associated with increased risk of myelofibrotic transformation in ET cases. (References: PMID: 36347013)